Abstract
We describe a patient with widespread and progressive cutaneous sarcoidosis who was successfully treated with anti-tumor necrosis factor-alpha monoclonal antibody, infliximab, suggesting that inhibition of tumor necrosis factor-alpha may be useful as targeted treatment in cutaneous sarcoidosis.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / therapeutic use*
-
Dermatologic Agents / therapeutic use*
-
Disease Progression
-
Genotype
-
Humans
-
Infliximab
-
Male
-
Sarcoidosis / drug therapy*
-
Sarcoidosis / genetics
-
Skin Diseases / drug therapy*
-
Tumor Necrosis Factor-alpha
Substances
-
Antibodies, Monoclonal
-
Dermatologic Agents
-
Tumor Necrosis Factor-alpha
-
Infliximab